Headache News and Research RSS Feed - Headache News and Research

Modified surgical technique may be effective treatment option for chronic temporal headache

Modified surgical technique may be effective treatment option for chronic temporal headache

A modified surgical technique may provide a simpler approach to the surgical treatment for one type of chronic headache, according to an "Ideas and Innovations" paper in the May issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS). [More]
First generic version of Crestor gets FDA approval

First generic version of Crestor gets FDA approval

The U.S. Food and Drug Administration today approved the first generic version of Crestor (rosuvastatin calcium) tablets. [More]
More neurological resources needed to manage Zika virus infections

More neurological resources needed to manage Zika virus infections

WFN Zika-Info-Service: World Federation of Neurology establishes Work Group on Zika virus to support international efforts - Lack of neurological resources in countries most concerned by the virus. [More]
Study highlights significant burden of migraine on family activities

Study highlights significant burden of migraine on family activities

The debilitating pain and disability of migraine also attacks the emotional, social and financial fabric of a family, according to a new study conducted by researchers at Montefiore Headache Center, Albert Einstein College of Medicine, affiliated with the Uniformed Services University of the Health Sciences, Vedanta Research, the Mayo Clinic and Allergan plc. The findings were published today in Volume 91, Issue 5 of Mayo Clinic Proceedings. [More]
Updated guidance on botulinum toxin formulations for four indications

Updated guidance on botulinum toxin formulations for four indications

The American Academy of Neurology has issued an update to its 2008 guidelines on the use of botulinum toxin for the treatment of spasticity, cervical dystonia, blepharospasm and migraine headache. [More]
Bupropion, varenicline drugs do not increase risk of serious neuropsychiatric adverse events

Bupropion, varenicline drugs do not increase risk of serious neuropsychiatric adverse events

Compared to the nicotine patch and a placebo, the smoking cessation aids varenicline (marketed as Chantix in the U.S.) and bupropion (Zyban) do not show a significant increase in neuropsychiatric adverse events, reports an international team of researchers in a study published online April 22 in the journal The Lancet. [More]
Study aims to determine how aches, pains before and after concussion play role in recovery

Study aims to determine how aches, pains before and after concussion play role in recovery

Athletes who have medical complaints, like aches and pains, that have no known physical cause may take longer to recover after a concussion, according to a study published in the April 20, 2016, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
Duke-NUS study highlights Zika virus structure and behaviour

Duke-NUS study highlights Zika virus structure and behaviour

An important breakthrough in understanding the Zika virus structure and its behaviour has been highlighted in a study by Duke-NUS Medical School scientists. [More]
AAN’s updated guideline on botulinum toxin use covers four neurologic disorders

AAN’s updated guideline on botulinum toxin use covers four neurologic disorders

The American Academy of Neurology has updated its 2008 guidelines on the use of botulinum toxin for spasticity, cervical dystonia, blepharospasm and migraine headache, based on recent research. [More]
AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

AbbVie, a global biopharmaceutical company, today announced that 91 percent (n=20/22) of genotype 1 (GT1) chronic hepatitis C virus (HCV) infected patients who failed previous therapy with direct-acting antivirals (DAAs) achieved SVR12 with 12 weeks of ABT-493 and ABT-530 with ribavirin (RBV) in the primary intent-to-treat analysis. [More]
VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

AbbVie, a global biopharmaceutical company, today announced new real-world data showing 96 percent of genotype 1 (GT1) patients (n=486/505 assessable for analysis) and 100 percent (n=53/53) of genotype 4 (GT4) patients achieved sustained virologic response at 12 weeks post-treatment (SVR12). [More]
New KidsMD Alexa skill device allows parents to get easier to access medical information

New KidsMD Alexa skill device allows parents to get easier to access medical information

"My child has a fever of 101. Should I be concerned?" Through a new skill created for Amazon Alexa-enabled devices, parents will now be able to ask Alexa a variety of questions around fever and other common symptoms. The KidsMD Alexa skill was developed by the Innovation & Digital Health Accelerator team at Boston Children's Hospital and launched today. [More]
Inflectra (infliximab-dyyb) approved for multiple indications

Inflectra (infliximab-dyyb) approved for multiple indications

The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA. [More]
Janssen announces CHMP positive opinion for use of paliperidone palmitate 3-monthly injection for schizophrenia treatment

Janssen announces CHMP positive opinion for use of paliperidone palmitate 3-monthly injection for schizophrenia treatment

Janssen UK announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the use of paliperidone palmitate 3-monthly injection for the maintenance treatment of schizophrenia in the European Union. [More]
NICE issues positive guidance on use of electroCore’s gammaCore treatment for migraine and cluster headache

NICE issues positive guidance on use of electroCore’s gammaCore treatment for migraine and cluster headache

The UK’s National Institute of Health and Care Excellence has published guidance that electroCore’s non-invasive vagus nerve stimulation treatment (gammaCore) for the prevention and acute treatment of migraine and cluster headache is safe and can now be used in the NHS. [More]
Investigators predict that new pneumonia epidemic in Beijing will likely to continue for longer time

Investigators predict that new pneumonia epidemic in Beijing will likely to continue for longer time

Mycoplasma pneumoniae infections began rising in Beijing last spring, and by December, this pathogen was found in more than half of hospitalized children suffering from pneumonia in that city, according to investigators from the Capital Institute of Pediatrics, Beijing, China. [More]
Sleep problems predict chronic pain in emerging adults

Sleep problems predict chronic pain in emerging adults

For at least some groups of "emerging adults," sleep problems are a predictor of chronic pain and worsening pain severity over time, suggests a study in PAIN, the official publication of the International Association for the Study of Pain. [More]
Symptom Tracking App for Concussions helps athletes, parents deal with head injuries

Symptom Tracking App for Concussions helps athletes, parents deal with head injuries

Thirteen-year-old Madeline Yunker fell hard during a soccer match three years ago, striking her head on the turf with enough force to cause a concussion. [More]
Four commonly used medications to treat pregnant women with migraines may not be safe

Four commonly used medications to treat pregnant women with migraines may not be safe

According to doctors at Wake Forest Baptist Medical Center, medications and treatments long considered safe to treat pregnant women with migraines may not be. [More]
IUPUI assistant professor to study role of deficient pain modulatory systems on post-traumatic headaches

IUPUI assistant professor to study role of deficient pain modulatory systems on post-traumatic headaches

An assistant professor in the Department of Kinesiology in the IU School of Physical Education and Tourism Management at Indiana University-Purdue University Indianapolis has been awarded a grant to study the role of deficient pain modulatory systems on chronic post-traumatic headaches afflicting hundreds of thousands of people with mild traumatic brain injuries. [More]
Advertisement
Advertisement